{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:35:59Z","timestamp":1789097759509,"version":"build-2803163510"},"reference-count":20,"publisher":"Japan Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej24-0575","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:12:16Z","timestamp":1740157936000},"page":"663-670","source":"Crossref","is-referenced-by-count":4,"title":["Influence of therapeutic inorganic iodine on long-term prognosis of Graves\u2019 disease: a multicenter prospective observational study"],"prefix":"10.1507","volume":"72","author":[{"given":"Hiroki","family":"Takizawa","sequence":"first","affiliation":[{"name":"Department of Metabolism &amp; Endocrinology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4301-2955","authenticated-orcid":false,"given":"Toyoyoshi","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Metabolism &amp; Endocrinology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2877-6647","authenticated-orcid":false,"given":"Nami","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ito Hospital, Tokyo 150-8308, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9244-3493","authenticated-orcid":false,"given":"Hiroyuki","family":"Onose","sequence":"additional","affiliation":[{"name":"Kanaji Thyroid Hospital, Tokyo 114-0015, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Yamada","sequence":"additional","affiliation":[{"name":"Kanaji Thyroid Hospital, Tokyo 114-0015, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3530-689X","authenticated-orcid":false,"given":"Koshi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Saitama 343-0845, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2297-5004","authenticated-orcid":false,"given":"Natsuko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ito Hospital, Tokyo 150-8308, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Metabolism &amp; Endocrinology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Watada","sequence":"additional","affiliation":[{"name":"Department of Metabolism &amp; Endocrinology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Hamburger JI (1981) Chapter 6: is there a place for long-term stable iodine in the treatment of Graves\u2019 disease? In: Hamburger JI, Miller JM (eds) Controversies in clinical thyroidology. Springer, New York, USA: 159\u2013183.","DOI":"10.1007\/978-1-4612-5916-9_6"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2 Uchida T, Goto H, Kasai T, Komiya K, Takeno K, et al. (2014) Therapeutic effectiveness of potassium iodine in drug-na\u00efve patients with Graves\u2019 disease: a single-center experience. Endocrine 47: 506\u2013511.","DOI":"10.1007\/s12020-014-0171-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Suzuki N, Yoshimura Noh J, Sugisawa C, Hoshiyama A, Hiruma M, et al. (2020) Therapeutic efficacy and limitations of potassium iodide for patients newly diagnosed with Graves\u2019 disease. Endocr J 67: 631\u2013638.","DOI":"10.1507\/endocrj.EJ19-0379"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, et al. (2008) Long-term follow-up of patients with hyperthyroidism due to Graves\u2019 disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation <i>vs.<\/i> continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 31: 866\u2013872.","DOI":"10.1007\/BF03346433"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Azizi F, Amouzegar A, Tohidi M, Hedayati M, Khalili D, et al. (2019) Increased remission rates after long-term methimazole therapy in patients with Graves\u2019 disease: results of a randomized clinical trial. Thyroid 29: 1192\u20131200.","DOI":"10.1089\/thy.2019.0180"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Morales Garc\u00eda F, Cayuela A, Garc\u00eda Hern\u00e1ndez N, Losada Vi\u00f1au F, Mangas Cruz M, et al. (2008) Long-term maintenance of low-dose antithyroid drugs <i>versus<\/i> drug withdrawal in patients with Graves\u2019 hyperthyroidism. Endocrinol Nutr 55: 123\u2013131.","DOI":"10.1016\/S1575-0922(08)70648-X"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7 Azizi F, Amouzegar A, Khalili D, Abdi H, Tohidi M, et al. (2024) Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves\u2019 hyperthyroidism: a randomized trial and a risk-scoring model. Endocrine 84: 577\u2013588.","DOI":"10.1007\/s12020-023-03656-5"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8 Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, et al. (2006) Serum thyrotropin receptor antibodies concentrations in patients with Graves\u2019 disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and\/or thyroid response modify during the observation period. Thyroid 16: 295\u2013302.","DOI":"10.1089\/thy.2006.16.295"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Okamoto Y, Tanigawa S, Ishikawa K, Hamada N (2006) TSH receptor antibody measurements and prediction of remission in Graves\u2019 disease patients treated with minimum maintenance doses of antithyroid drugs. Endocr J 53: 467\u2013472.","DOI":"10.1507\/endocrj.K05-121"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Konishi T, Okamoto Y, Ueda M, Fukuda Y, Harusato I, et al. (2011) Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves\u2019 disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr J 58: 95\u2013100.","DOI":"10.1507\/endocrj.K10E-262"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11 Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, et al. (2016) 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26: 1343\u20131421.","DOI":"10.1089\/thy.2016.0229"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Kashiwai T, Hidaka Y, Takano T, Tatsumi KI, Izumi Y, et al. (2003) Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves\u2019 disease. Endocr J 50: 45\u201349.","DOI":"10.1507\/endocrj.50.45"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Werner RS, Romaldini JH, Farah CS, Werner MC, Bromberg N (1991) Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves\u2019 disease. Thyroid 1: 293\u2013299.","DOI":"10.1089\/thy.1991.1.293"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Thompson WO, Thompson TP, Brailey AG, Cohen AC (1930) Prolonged treatment of exophthalmic goiter by iodine alone. Archives of Internal Medicine 45: 481\u2013502.","DOI":"10.1001\/archinte.1930.00140100003001"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15 Hashimoto K, Nishihara E, Matsumoto M, Matsumoto S, Nakajima Y, et al. (2018) Sialic acid-binding immunoglobulin-like lectin1 as a novel predictive biomarker for relapse in Graves\u2019 disease: a multicenter study. Thyroid 28: 50\u201359.","DOI":"10.1089\/thy.2017.0244"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Tajiri J, Noguchi S, Morita M, Tamaru M, Murakami N (1991) Antithyroid drug therapy for Graves\u2019 hyperthyroidism: is long-term administration of a small maintenance dose necessary? Endocrinol Jpn 38: 223\u2013227.","DOI":"10.1507\/endocrj1954.38.223"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Mashio Y, Beniko M, Matsuda A, Koizumi S, Matsuya K, et al. (1997) Treatment of hyperthyroidism with a small single daily dose of methimazole: a prospective long-term follow-up study. Endocr J 44: 553\u2013558.","DOI":"10.1507\/endocrj.44.553"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Madec AM, Laurent MC, Lorcy Y, Le Guerrier AM, Rostagnat-Stefanutti A, et al. (1984) Thyroid stimulating antibodies: an aid to the strategy of treatment of Graves\u2019 disease? Clin Endocrinol (Oxf) 21: 247\u2013255.","DOI":"10.1111\/j.1365-2265.1984.tb03466.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, et al. (1990) Antithyroid drugs and Graves\u2019 disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 70: 675\u2013679.","DOI":"10.1210\/jcem-70-3-675"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Izumi Y, Takeoka K, Amino N (2005) Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves\u2019 thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves\u2019 disease. Endocr J 52: 493\u2013497.","DOI":"10.1507\/endocrj.52.493"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/6\/72_EJ24-0575\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:41:39Z","timestamp":1749256899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/6\/72_EJ24-0575\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0575","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ24-0575"}}